National Drug Abuse Treatment Clinical Trials Network February 13, 2003 Betty Tai, Ph.D. Director, Center for the Clinical Trials Network, NIDA/NIH February.

Slides:



Advertisements
Similar presentations
Evidence Based Practices Lars Olsen, Director of Treatment and Intervention Programs Maine Department of Corrections September 4, 2008.
Advertisements

Implementation Science Retreat March 1, 2013 Louise Haynes, MSW Leslie Wilson, MA Adoption of HIV Counseling and Testing Following Completion of Randomized.
Integrated Substance Abuse Programs Bridges have been built: Is anyone using them? Richard A. Rawson, Ph.D, Professor Supported by: National Institute.
We Still Haven’t Come a Long Way, Baby! Smoking Cessation Efforts in an Oregon CTP Lucy Zammarelli – Willamette Family, Inc. Barbara Tajima, University.
Complexities of Co-occurring Disorders STATE AGENCY PERSPECTIVE June 24, 2004 Renata J. Henry, M.Ed.
Overview of Outreach competencies Stephen J. Gumbley, MA, ACDP II Director, New England ATTC.
Center for Innovative the Begun Center for Violence Prevention Research and Education 1.
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Principles of Drug Addiction Treatment: What Works with Offenders? Rita Dries July 2006.
Project Overview NE FTCC Trainers’ Capacity Building Training May 24-25, 2010 at Mohonk Mountain House, New Paltz, NY Training Objectives: – Increase awareness.
Comparative Effectiveness Research in the National Drug Abuse Treatment Clinical Trials Network (CTN) CDR Steven Sparenborg, Ph.D., Udi Ghitza, Ph.D.,
What the Heck is the CTN Anyway? The NIDA National Drug Abuse Treatment Clinical Trials Network.
Motivational Interviewing to Improve Treatment Engagement and Outcome* The effect of one session on retention Research findings from the NIDA Clinical.
3-1 Lori L. Phelps California Association for Alcohol/Drug Educators, 2013.
Addiction Health Services Research Conference Lexington, KY Louise Haynes, MSW Adoption of HIV Counseling and Testing Following Completion of Randomized.
Outpatient Services Programs Workgroup: Service Provision under Laura’s Law June 11, 2014.
HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,
States and Substance Abuse Treatment Programs: Priorities, Guidelines and Funding for Infection-related Services S. Kritz, MD; L.S. Brown, MD, MPH; R.
Behavioral Interventions for HIV Risk Reduction and HIV Prevention: An International Perspective Marek C. Chawarski Yale University School of Medicine.
SUBSTANCE USE DISORDERS GENERAL METHODS OF TREATMENT Inpatient Detoxification and Rehabilitation Outpatient Individual, Couple, or Family Counseling Self-help.
Attractive Addiction Treatment...? Can we make addiction treatment engaging?
Audrey J. Brooks, PhD University of Arizona CA-AZ node.
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
NIDA/SAMHSA Blending Initiative Overview. Advances in science are giving us a broad range of promising options for treating substance use disorders, BUT.
Mental Health and Substance Abuse Services Joe Vesowate Assistant Commissioner.
The Value of Ongoing Evaluation in Adopting Buprenorphine-Naloxone Short-term Taper Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley.
Harold I Perl, PhD Center for the Clinical Trials Network National Institute on Drug Abuse NIATx Summit and SAAS National Conference Boston, MA July 13,
FUTURE HIV RESEARCH EFFORTS PLANNED FOR THE CLINICAL TRIALS NETWORK James L. Sorensen, Ph.D. Susan Tross, Ph.D. Raul Mandler, M.D. University of California,
Implementation Science and the Adoption of Practice in Addiction Treatment Harold I Perl, PhD Center for the Clinical Trials Network National Institute.
Relationships between State Policies and the Availability of Services for HIV/AIDS, Hepatitis C Viral Infection, and Sexually Transmitted Infections in.
KENTUCKY YOUTH FIRST Grant Period August July
Clinicians Involved in Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infection, and Sexually Transmitted Infections in Substance.
Implementation of Evidence-Based Models: Improving Processes Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute UCLA Integrated Substance Abuse.
NATIONAL INSTITUTE ON DRUG ABUSE NID A A Recent Scientific and Process Publications from the Clinical Trials Network Betty Tai, Ph.D. Harold Perl, Ph.D.
EVALUATING THE IMPACT OF ADDING THE RECLAIMING FUTURES APPROACH TO JUVENILE TREATMENT DRUG COURTS: RECLAIMING FUTURES/JUVENILE DRUG COURT EVALUATION Josephine.
Specific Aims  Modify a previously used ACASI (audio computer assisted structured interview) assessment tool, the Sexual Behavior Inventory (SBI), for.
Relationships Between HIV Disease Knowledge, Opinions, Training, Experience, And Service Availability At Substance Abuse Treatment Programs Data Source.
HIV/AIDS-Related Services in Substance Abuse Treatment Settings: Preliminary Results The NIDA Clinical Trials Network Lawrence S. Brown, Jr., MD, MPH,
MIA: STEP Toolkit Overview. NIDA-SAMHSA Blending Initiative 2 What is an MI Assessment?  Use of client-centered MI style  MI strategies that can be.
USING STANDARDIZED PATIENTS TO PILOT SCREENING VISITS IN CLINICAL TRIALS Lynn E. Kunkel, M.S., Holly Fussell, Ph.D., Colleen Shannon-Lewy, Ph.D., & Bentson.
Integrating Services Research into CTN Clinical Trials: The Devil is in the Details Harold I Perl, PhD Center for the Clinical Trials Network National.
Elizabeth WellsDennis Daley School of Social WorkWestern Psychiatric Institute University of WashingtonUniversity of Pittsbu rgh Supported by Grants #
Michael Levy, Ph.D. VP of Clinical Services Northeast Behavioral Health.
Federally Qualified Health Centers (FQHCs): Addressing the Challenges of Health Care Reform Community Treatment Program (CTP) Caucus Clinical Trials Network.
PAMI Promoting Awareness of Motivational Incentives: Focus on Founding Principles and an Implementation Checklist Donald A Calsyn, Ph.D. Pacific Northwest.
Monitoring the Progress of Clinical Trials in a Network Setting: Experience from the National Drug Abuse Treatment Clinical Trials Network P. VanVeldhuisen.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2014.
Adoption of HIV Counseling and Testing Following Completion of Randomized Clinical Trial Louise Haynes 1, Beverly Holmes 2 Camille Peay 2, Lisa Metsch.
Buprenorphine and the NIDA CTN: Research to Practice Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo,
Adoption of a rapid HIV testing and counseling program facilitates state-wide implementation B. Holmes 1, L. Haynes 2, J.Korte 2, K. Brady 2 1 Lexington-Richland.
National Drug Abuse Treatment Clinical Trials Network Dissemination Library Meg Brunner, MLIS; Nancy Sutherland, MLS.
Addiction Treatment in Israel: An Overview of Services Provision Iris Mordecovitch, MSW.
Adoption of HIV Counseling and Testing Following Completion of Randomized Clinical Trial Louise Haynes 1, Beverly Holmes 2, Anna Amberg 2, Kathleen Brady.
Clarity of State Guidance on Infection-Related Health Services in Substance Abuse Treatment Programs L.S. Brown, MD, MPH; S. Kritz, MD; J. Rotrosen, MD;
TREATMENT OF SUBSTANCE USE DISORDERS TX myths 1. Nothing works 2. One approach is superior to all others (“one true light” tradition) 3. All treatment.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Predictors of study retention in addiction treatment trials KORTE JE 1, MAGRUDER KM 1,2, KILLEEN TK 1, SONNE SC 1, SAMPSON RR 1 and BRADY KT 1,2 1. Medical.
Gaps in Substance Use Treatment Presented by: Rhonda G. Patrick, LCSW, MPA Amy C. Traylor, MSW, Ph.D.
Meg Brunner, MLIS; Nancy Sutherland, MLS Alcohol and Drug Abuse Institute, University of Washington (WA Node) The NATIONAL DRUG ABUSE TREATMENT CLINICAL.
CTN Update Betty Tai, Ph.D February 14, 2001 Who could want a more lovely way To spend Valentine’s Day Than talking about how we may Implement protocols.
TRANSDISCIPLINARY FOUNDATION II: TREATMENT KNOWLEDGE Contributor: Lori Phelps Lori L. Phelps California Association for Alcohol/Drug Educators, 2015 Chapter.
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
The Center for the Treatment of Problem Sexual Behavior The Connection, Inc. Program Description January 7,
Harold I Perl, PhD Center for the Clinical Trials Network National Institute on Drug Abuse 8 th Conference of INEBRIA Boston, MA September 23, 2011.
State of the Science in Functional Family Therapy
Predictors of study retention in drug abuse treatment trials
Hatch-Maillette, M. 1, Calsyn, D. A1,2, Doyle, S. 1, Woods, A
Using Observation to Enhance Supervision CIMH Symposium Supervisor Track Oakland, California April 27, 2012.
Overview of the Addiction Technology Transfer Center Network
Treatment for PTSD and SUD:
Presentation transcript:

National Drug Abuse Treatment Clinical Trials Network February 13, 2003 Betty Tai, Ph.D. Director, Center for the Clinical Trials Network, NIDA/NIH February 13, 2003 Betty Tai, Ph.D. Director, Center for the Clinical Trials Network, NIDA/NIH

Who could want a more lovely way To spend Valentine’s Day Than talking about how we may Implement protocols the CTN way Who could want a more lovely way To spend Valentine’s Day Than talking about how we may Implement protocols the CTN way

CTN’s Mission To Improve Drug Abuse Treatment Throughout the Nation… Using SCIENCE as the Vehicle To Improve Drug Abuse Treatment Throughout the Nation… Using SCIENCE as the Vehicle

Uniqueness of CTN Blending Research and Practice Bi-directional Collaboration Multi-node, Multi-site RCTs Rigorous Scientific Standards Real World Approach Dissemination End-products Targeted Blending Research and Practice Bi-directional Collaboration Multi-node, Multi-site RCTs Rigorous Scientific Standards Real World Approach Dissemination End-products Targeted

CTN Where the Rubber Meets the Road A Paradigm Shift: Transferability, Acceptability, Sustainability

CTN Development Update FY 2000 FY 2001 FY 2003 FY Protocol Projects………12………21………26……… Dissemination New Research Agenda (HIV, CJS, etc.) New Concepts & Protocols (Ongoing) Build & Maintain Infrastructure……5…….11………14……….17 Establish Policies and SOPs

National Drug Abuse Treatment Clinical Trials Network Node RRTC – Regional Research and Training Center CTP – Community-Based Treatment Program RRTC – Regional Research and Training Center CTP – Community-Based Treatment Program CTP RRTC

National Drug Abuse Treatment Clinical Trials Network National Drug Abuse Treatment Clinical Trials Network Oregon Node OHSU Washington Node U. Washington Pacific Node UCLA Rocky Mountain Node U. Colorado Florida Node U. Miami Great Lakes Node Wayne State U. Ohio Valley Node U. Cincinnati South Carolina Node MUSC North Carolina Node Duke California/Arizona Node UCSF/U. Arizona Southwest Node U. New Mexico Northern NE Node McLean/Harvard New England Node Yale New York Node NYU Long Island Node NY State Psych. Inst. Delaware Valley Node U. Pennsylvania Mid-Atlantic Node JHU/MCV 17 Regional Research and Training Centers working in partnership with 115 Community-Based Treatment Programs across 27 States

Infrastructure

CTN Administrative Overview NIDA Grants Management Branch Ad Hoc Oversight PRB DSMB CCTN Contract Support CTN Nodes Repository Steering Committee NIDA Director New EnglandNew York Delaware Valley Mid-Atlantic OregonPacific South Carolina Florida Great LakesOhio Valley Rocky Mountain Long Island Washington North Carolina California/ Arizona New Mexico Northern New England

Steering Committee Research PortfolioOperationsExternal Affairs Executive Committee

Administration OD ScienceOperationsDissemination Center for the Clinical Trials Network Steering Committee Research PortfolioOperationsExternal Affairs Executive Committee Review Data Informatics

CTN Rules CTN Bylaws CTN Node Performance Index CTN Operations Guidebook CTN Study Integrity Monitoring Standards –Medication Trials –Behavioral Trials CTN Study Safety Monitoring System CTN Bylaws CTN Node Performance Index CTN Operations Guidebook CTN Study Integrity Monitoring Standards –Medication Trials –Behavioral Trials CTN Study Safety Monitoring System

Research Concept Generation NIDA CTN CTN Steering Committee Network Oversight Board NIDA Director Concepts CTN Nodes CTPs Protocol Development

CTN Protocol Portfolio – 2002 Project #Protocol TitleLI CTN 0001Bup/Nal vs Clonidine for Inpatient Opiate DetoxLing CTN 0002Bup/Nal vs Clonidine for Outpatient Opiate DetoxLing CTN 0003Bup/Nal: Comparison of Three Taper Schedules for Opiate DetoxAmass CTN 0004 MET (Motivational Enhancement Treatment) To Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse Carroll CTN 0005 MI (Motivational Interviewing) To Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse Carroll CTN 0006Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone ClinicsStitzer CTN 0007Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free ClinicsStitzer CTN 0008Baseline SurveyGreenlick CTN 0009 Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy in Substance Abuse Rehabilitation Program Reid CTN 0010Bup/Nal in the Treatment of Adolescent and Young Adult Heroin AddictsWoody CTN 0011Telephone Enhancement of Long-Term EngagementHubbard CTN 0012Infections Screening in Substance Abuse Treatment ProgramsBrown CTN 0013Motivational Interviewing for Pregnant Women Seeking Substance Abuse TreatmentWinhusen CTN 0014Brief Strategic Family Therapy for Adolescent Drug AbusersSzapocznik CTN 0015 Women’s Treatment for Substance Use Disorders and Trauma in Inpatient Rehabilitation and Intensive Outpatient Settings Hien CTN 0016Patient Feedback: A Performance Improvement StudyForman CTN 0017HIV/HCV Intervention in Drug Treatment SettingsBooth CTN 0018HIV/STD Safer Sex Skills Groups for MenCalsyn CTN 0019HIV/STD Safer Sex Skills Groups for WomenTross CTN 0020Job Seekers Training for Clients with Drug DependenceSvikis CTN 0021MET or MI: Spanish versionCarroll

Current CTN Portfolio (21 Protocols) By Intervention Type

Current CTN Portfolio (21 Protocols) Total Projected Enrollment by Intervention Type

Current CTN Portfolio (21 Protocols) Protocols Involving Special Populations

Status of Current Trials: > 1,900 Patients Enrolled Protocol NIDA-CTN- Short Title Number Randomized Enrollment Target 0001Bup/Nx Inpatient113Closed 0002Bup/Nx Outpatient233Closed 0004MET MI400Closed 0006Incentives Drug-Free Incentives Methadone TELE13360

CTN Special Interest Groups 1.HIV/AIDS 2.Adolescent 3.Women and Gender 4.Co-morbidity 5.Court-involved Patients 6.Ethnic Minority 7.Behavioral Therapy 8.Buprenorphine 9.Treatment match 10.Smoking 11.Homelessness 12.Spirituality 1.HIV/AIDS 2.Adolescent 3.Women and Gender 4.Co-morbidity 5.Court-involved Patients 6.Ethnic Minority 7.Behavioral Therapy 8.Buprenorphine 9.Treatment match 10.Smoking 11.Homelessness 12.Spirituality

1.Generate snapshots of current practice 2.Identify empirically supported interventions 3.Develop high quality research concepts  4 AIDS concepts  3 Women concepts  2 Adolescent concepts  3 Co-morbidity concepts 4.Identify and develop special research tools 5.Develop long range research plan 6.Serve as expert resources 1.Generate snapshots of current practice 2.Identify empirically supported interventions 3.Develop high quality research concepts  4 AIDS concepts  3 Women concepts  2 Adolescent concepts  3 Co-morbidity concepts 4.Identify and develop special research tools 5.Develop long range research plan 6.Serve as expert resources CTN Special Interest Group

CTN as Research Platform Currently 4 RO1s from Services Research Branch –Managed by CTN Research Liaison Sub-C A new PA released from SRB Bup/NX Post Marketing Survey from Pharmaceutical Co. Other collaborations welcome Currently 4 RO1s from Services Research Branch –Managed by CTN Research Liaison Sub-C A new PA released from SRB Bup/NX Post Marketing Survey from Pharmaceutical Co. Other collaborations welcome

National CTN Symposia: /03 – AATOD 5/03 – ASAM, NCDEU 6/03 – NASADAD, CPDD, RSA 7/03 – SCT 8/03 – APsychologicalA 9/03 – ICTAB-10, Blending Meeting 4/03 – AATOD 5/03 – ASAM, NCDEU 6/03 – NASADAD, CPDD, RSA 7/03 – SCT 8/03 – APsychologicalA 9/03 – ICTAB-10, Blending Meeting

CTN By-Products Appreciation of Research/Science in the CTPs Change of Practice Attitudes –Buprenorphine detox for patients in drug-free clinics –TAU has been greatly modified Training –GCP/CAB training on regular basis –80 therapists trained/certified for MI –LIs training in leading complex clinical trials NIDA’s presence in Community Treatment Programs Appreciation of Research/Science in the CTPs Change of Practice Attitudes –Buprenorphine detox for patients in drug-free clinics –TAU has been greatly modified Training –GCP/CAB training on regular basis –80 therapists trained/certified for MI –LIs training in leading complex clinical trials NIDA’s presence in Community Treatment Programs

CTN Challenges Gaps Between Researchers and Practitioners –Culture –Interests Clinical Trials in Real-World Settings –Protocol Design & Analysis –Protocol Implementation Gaps Between Researchers and Practitioners –Culture –Interests Clinical Trials in Real-World Settings –Protocol Design & Analysis –Protocol Implementation

Concept Selection Criteria Researchers’ perspectives Need scientific evidence Need pilot data Need dose response Need sample size/power considerations Need adequate data analysis Need data to focus future studies Need assurance of data integrity Need scientific evidence Need pilot data Need dose response Need sample size/power considerations Need adequate data analysis Need data to focus future studies Need assurance of data integrity

Evidence Criteria Researchers –Published in JAMA –Replicated –Large sample with good power Researchers –Published in JAMA –Replicated –Large sample with good power Practitioners –Everyone is doing it –State mandated –It worked for my patients Practitioners –Everyone is doing it –State mandated –It worked for my patients How to address bi-directionality issues? How to develop “science-based” practice?

Concept Selection Criteria Practitioners’ perspectives Need relevance in real life settings 1.How much internal/external validity? 2.How representative are the samples? 3.How does this deviate from practice? 4.How expensive? Who pays for this? 5.Any impact on long-term outcome? 6.Do my patients accept it? Need relevance in real life settings 1.How much internal/external validity? 2.How representative are the samples? 3.How does this deviate from practice? 4.How expensive? Who pays for this? 5.Any impact on long-term outcome? 6.Do my patients accept it?

Challenges: Research Design and Analysis Determining Control Treatment Placebo control Ethics Feasibility Bup/Nx vs. clonidine detox trial Open trial for feasibility Patients’/clinicians’ bias uncontrolled Placebo control Ethics Feasibility Bup/Nx vs. clonidine detox trial Open trial for feasibility Patients’/clinicians’ bias uncontrolled Pharmacotherapies

Challenges: Research Design and Analysis Determining Control Treatment Standardized control Relevance for individual sites Treatment-as-usual (TAU) control Wide variability of TAU between and within sites and over time Difficulty of analyzing multi-site, multi-TAU data Many trials need to describe and monitor TAUs Standardized control Relevance for individual sites Treatment-as-usual (TAU) control Wide variability of TAU between and within sites and over time Difficulty of analyzing multi-site, multi-TAU data Many trials need to describe and monitor TAUs Behavioral Therapies

Implementation Challenges: Accommodating the Real World User friendly Transferable KISS Protocol language Standardized procedures across sites –Quality data output –Quality Assurance User friendly Transferable KISS Protocol language Standardized procedures across sites –Quality data output –Quality Assurance

Training –Research experience varies –Fidelity and monitoring –Staff turnover Assessment batteries –Which instruments? Validated? –How much time? –Redundancy? Open vs. blinded –Bleeding or contamination Training –Research experience varies –Fidelity and monitoring –Staff turnover Assessment batteries –Which instruments? Validated? –How much time? –Redundancy? Open vs. blinded –Bleeding or contamination Implementation Challenges: Accommodating the Real World

Opportunities A Frontier of Research Researchers and Practitioners are Fully aware of the challenges Determined to conquer them Willing to cooperate

CTN trials completed in 2002: Buprenorphine/Naloxone Detoxification Change in programs’ attitudes Change in medical management of opiate addiction Adolescent, Dose Tapering trials Motivational Enhancement Therapy/Motivational Interviewing (MET/MI) 80 therapists trained/certified Complement to usual practice Spanish MET trial Buprenorphine/Naloxone Detoxification Change in programs’ attitudes Change in medical management of opiate addiction Adolescent, Dose Tapering trials Motivational Enhancement Therapy/Motivational Interviewing (MET/MI) 80 therapists trained/certified Complement to usual practice Spanish MET trial Clinical Trials Network

Completed and Ongoing Studies Medication Therapies Buprenorphine/Naloxone Detoxification –Inpatient/Outpatient Behavioral Therapies Motivational Enhancement Therapy (MET)/Motivational Interviewing (MI) Motivational Incentives Therapy –Drug-Free Clinics/Methadone Clinics TELE Engagement Procedure Surveys Baseline Survey of CTPs Medication Therapies Buprenorphine/Naloxone Detoxification –Inpatient/Outpatient Behavioral Therapies Motivational Enhancement Therapy (MET)/Motivational Interviewing (MI) Motivational Incentives Therapy –Drug-Free Clinics/Methadone Clinics TELE Engagement Procedure Surveys Baseline Survey of CTPs

Studies to Begin Enrollment in 2003 Bup/Nx Tapering Schedules Smoking Cessation Treatment in Substance Rehabilitation Programs Bup/Nx for Adolescents Infections and Substance Abuse Survey MET for Pregnant Substance Users Brief Strategic Family Therapy Women’s Treatment for Trauma and Substance Use Disorders Bup/Nx Tapering Schedules Smoking Cessation Treatment in Substance Rehabilitation Programs Bup/Nx for Adolescents Infections and Substance Abuse Survey MET for Pregnant Substance Users Brief Strategic Family Therapy Women’s Treatment for Trauma and Substance Use Disorders

Studies Under Development Patient Feedback HIV/HCV Risk Reduction Intervention in Drug Treatment Settings HIV/STD Safer Sex Skills for Men/Women Job Seekers Training MET for Spanish Speaking Individuals HIV Risk Reduction Intervention for Adolescents Family Management Skills Community Reinforcement and Family Training SSRI Treatment of Comorbid Depression and Substance Dependence Individual 12-Step Facilitation Patient Feedback HIV/HCV Risk Reduction Intervention in Drug Treatment Settings HIV/STD Safer Sex Skills for Men/Women Job Seekers Training MET for Spanish Speaking Individuals HIV Risk Reduction Intervention for Adolescents Family Management Skills Community Reinforcement and Family Training SSRI Treatment of Comorbid Depression and Substance Dependence Individual 12-Step Facilitation